Introduction
Inherited FVII deficiencyisthe commonest of the rare congenital coagulation disordersw ith an estimatedp revalenceo ft he symptomatic individuals of 1:500,000 (1) .Numerous mutations (http://europium.csc.mrc.ac.uk) (2) causing this autosomal recessive disorder underlie considerableheterogeneity in genotype and phenotype (i.e. FVIIc) (3) . Indeed,clinical heterogeneity is a feature of this haemorrhagicdisorder, whichranges in severity from lethaltomild,orevenasymptomatic forms. FVII deficiency is not believedt ob ea ssociatedw ith completea bsenceo f functional FVII and this fact accords with data from knock-out micestudies, whichsuggest that acomplete absence of FVII is incompatible with life (4).The minimal FVII levelabletointeract with tissue factor to prevent lethalbleeding in humansubjects has not yetbeen defined (5, 6) .
Numerous publications, focusing on the moleculargenetics, FVIIs tructure/function analysis and pathophysiology of FVII 
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deficiency, have appeared in the literature (7) and are based on a noteworthy seriesofpatients (8) (9) (10) (11) (12) (13) . However, acomprehensive approach, particularlyone basedonclinical issuesand involving av eryl arge patient population, hasn ot yetb een forthcoming. Hence,nosystematic analysesondiseasepresentation and diagnosis are availableand issues, such as the relationshipbetween gender and bleeding tendency, thatare important in the context of an autosomal disease, remainlargelyunsolved.
The absence of as ystematic approacht oc lassifying FVII deficiencyi ng roups phenotypically homogeneous has precluded the evaluation and comparison of treatments; this is mainlya ttributablet ot he lacko faclear relationship between factor clotting activity and bleeding phenotype (2) . It is known thatF VII levels are modulatedb yF VII gene polymorphisms (14) , butt heir impact on the bleeding tendencya waits verification (9) . Thea vailability of an integrated clinical and genetic data setwould provide the opportunityfor evaluating the roleof molecular geneticst ou nderstand the clinicalh eterogeneity of the disease. To fill this void,wecarried outanextensive analysis of 515 subjectswith FVIIactivity from less than1%upto50% of normal.
Methods

Patientenrollment
Atotal of 515 subjects (264 females [age range 1-90], 251 males [age range 2-86]) were referred from 59 centers from Europe, Asia,Australia-NewZealand and the Americas (see list of participants in the Study Group)becauseaFVII deficiency(FVIIc <50% and/or acausativemutation) wasdiagnosed. Of these,202 subjects were asymptomatic and 313symptomatic.
Initially, data collection wascarried outwith suitedquestionnaires whichi ncludedt he following items: FVIIc activity and antigen levels; familyh istory; dateso fl aboratoryd iagnosis; datesofonset of bleeding and subsequent bleeding episodes(up to 22 clinicalvariables).The initial database wasthen completed to include data from DNAanalyses, specific phenotypic assays and missing clinicali nformation. Attending physicians were asked to fill in file blanksa nd individual subjectf ilesw ere checked and validated. In total, the database comprises41pri-mary and 18 derived variables/file-patient. Twenty-twofiles, not suitablefor the analysis, were discarded.
Theresearch protocolwas approvedbythe ReviewBoardof PalermoUniversity (the original institution of GM)and by the boards of each of the participating institutions.Acommon form for the patient informedconsent and study information wasdevelopedand used.
Geneticand coagulation studies
Forall DNAsamples availablemutations in the FVII gene were investigated by DNAsequencing of allcoding regions, exon/intron boundaries and the promoter region, according to previouslydescribed methods (12, 15) .
FVIIc levels were assayed using astandard one-stage method in the labo fe ach participating center (lowestd etection limit 1%). High sensitivity thromboplastins (InternationalSensitivity Index [ISI] close to 1, i.e.r ecombinanta nd human-derived reagents) were employedfor 82% of the sample assays. Rabbit brain and bovine thromboplastins were alsou sedt os creen for specificv ariants. rFVII in 2nMconditioned medium wasincubated 5minutes at 37°C with1nMhuman factor Xa (hFXa) (Sigma,StLouis, MO) in 50 microL final volume.After addition of 30 microL thromboplastin, FXa generation wasstarted with 40 nM human FX (Sigma). Reaction wasq uenched and fluorescence was measured as described above.
The assays were standardized with dilutions of poolednormalplasma (PNP)orofrecombinantwild-type (rWt) FVII. The assaywas calibrated using dilutions of poolednormal plasma or wild-type recombinant FVII, respectively.A tl eastt hreei ndependent sets of experiments were carried outfor each assay.
Recombinant FVII expression
RecombinantF VII molecules were obtained ( 16) mutagenesis (Stratagene,CA, USA) of thehuman FVII cDNA cloned in pcDNA3.1, usingt he following oligonucleotides: 5'CCGTGGCGCCACGGTCCTGGAGCCATG-G-3' and 5'GGAGTCCTCCTGCGAG CCCATTTCCCTAGC-CCAGC3'. Transfections were performed using the LipofectAmine 2000Reagent(Life Technologies, ME, USA).
Statisticalmethods
Descriptives tatisticsf or ordinala nd counting variablesw ere used (median, range and interquartiler ange-IQR). Since distributions were notn ormal, non-parametric statisticala nalyses were used (17, 18) : for the skewed distribution, non-parametric Wilcoxon test and χ 2 test (association and homogeneity) were used,and for n>2groups Kruskal-Wallis one-way analysis of variance with post-hoc pair-wise comparisons (Dunn'stest) were performed (18) .Odds Ratio (OR) with (1-α %) ConfidenceInterval(CI)were used to estimate bleeding risk. Multivariate regression analysis (ordinalproportionalodds logistic regression models) wasp erformed to assess the significanceo fv ariables after abackward selection (19) .P-value(p) <0.05 wasconsidered statistically significant. All analyses were carried outu sing the statistical packages SAS8.12 and S-PLUS 2000.
Results
Symptoms and disease presentation
We observeda ne xcess of symptomatic females (n=174/313, 56%) as comparedtomales (n=139/313,44%).The distribution of symptoms for genderi np atients with FVIId eficiencyi s shown in Table1. Age at symptom onset wascompared with age at laboratory diagnosis in the 209 patients for whom both timep oints were available. In 50.5%ofsubjects, diagnosis of FVII deficiencywas made at the same time or within 6months of symptom onset. The median age of symptom onset (7.2 y) wasdifferent from thatat diagnosis (11.6 y; p<0.0001).
The most frequent presenting symptoms, as recorded in at least 10 patients, were ranked in orderofmedian age at presentation (Fig. 1) .Comparison of the median age at presentation for specific symptoms yielded astatistically significant difference ( χ 2 =26.6, p=0.0004). In particular,median age of patients presenting with eithercentral nervous system (CNS) or gastrointestinal (GI) bleeds were lower(post hoc Dunn'stest) thanthose of patients presenting with bleeds in othersites, with the exception of hemarthrosis.
Figure2:Mutationalspectrum. Gray, horizontal barsdenote promoter and cDNA segments. Novelmutations areindicated above thebars. Identity and absolutefrequencies of mutationsdetected in morethan 5allelesare reported underthe bars; underlined: mutationsoccurring in CpG sites.
Classification of clinical phenotypes
In hemophilia Aand Bareliable classification of severity can be obtainedb yplasma factor VIII or IX activity levels. We found, instead,that 24 subjects with FVIIc levels below2%(testedwith humano rr ecombinantt hromboplastins in 18 and with rabbit thromboplastin in 6subjects) were either asymptomatic or hada very mild phenotype.Bycontrast 16 subjects with FVIIc levels above 5% ,m ost of them (70%)t estedw ith humano rr ecombinant thromboplastins,w ere affected by severe symptoms (GI in 10, hemarthrosis in 8and CNS in 1).
These observations lead us to propose ac linical classification basedonthe resultsreported in Figure 1 . Based on quality and number of symptoms, patients were classified as reportedin Table2.
Features of classified patients and their differences are reported in Table3 
Genotype-phenotype relationship
Mutations of the FVII gene were characterized in 313 subjects. Three additionalsubjects with FVIIc levels of 50% and no causative mutation detected were homozygous for common polymorphisms alreadyknown to be associated with decreasedFVII levels. In 12 furthersubjects, no mutation wasfound. In total, we detected103 different mutations.InFigure2wereport the gene distribution and prevalenceo fc hanges, including the 22 mutations detectedamong 10% of patients, which, to the best of our knowledge,havenot beenpreviouslyreported to the FVIImutation database (http://europium.csc.mrc.ac.uk) or describedi n other recent publications. Missense mutations were the most frequent and occurred in 248 subjects(73%),whereassplicing-site, nonsense and small deletion (<17 nucleotides) causing frameshift mutations were found in 25, 12 and 10 individuals, respectively. Af requent allele bearing ad ouble change, the missense Ala294Val mutation and as ingle nucleotide deletion, 11125delC, occurred in 68 subjects. Twenty-onemutations each occurredinatleast5patients and,amongst these,8were located in CpG sequences (Fig. 2) ,known to be 'hot spot' mutation sites. Among the genotypedsubjects, 98 (30.9%), 91 (28.7%)and 128 (40.4%)were homozygous, doubleheterozygousand heterozygous for FVII mutations,r espectively. All thes evere patients buto ne resulted either homozygotes or double heterozygotes for mutations (Table 3) . As imilarp roportion of homozygotes and double heterozygotesw as observed amongt he affected patients (Table 3 ) with as imilara ge at disease presentation (data not shown).The same wastruefor the other classes of severity. Carriership of the M2 allele (353Gln), knowntobeassociated with lowFVIIc levels (14, 20) wassimilarinsymptomatic (73%)and asymptomatic (69%)patients with FVIIdeficiency, and particularlya mong asymptomatic (70%) and symptomatic (79%) heterozygotes.
Theinfluence of the M2 allele on FVIIc levels wasapparent onlyinasymptomatic subjects: FVIIcmedian levels in homozygotesordoubly heterozygotes were 6% (M2-carriers) and 11.4% (noncarriers,p<0.05). Similarly,asymptomatic heterozygotes had levels of 37% (M2-carriers) and 47%(p<0.001). Multivariate analysis (sex, zigosity status, FVIIc and FVII antigenand all their twowaysinteraction), carriedout in the 313 symptomatic subjects revealed the followingindependent variablestobesignificantly associatedwith bleeding severity: FVIIc (coefficient -0.0474, p=0.03), and FVII genezygosity(homozygotes and double heterozygotes vs. heterozygotes, coefficient 1.16, p=0.018).
Whereas double heterozygotes(n=91, 14 asymptomatic and 77 symptomatic) were characterized by an extremem utational heterogeneity and by rare combinations,which hamperedaninformative genotype-phenotype analysis, homozygoteswere usefulfor this purpose.
Our study provides information on 98 subjects (15 asymptomatic and 83 symptomatic) homozygous for 36 different mutations. Twenty-sevenp atients were classified as mild,2 6a s moderate, and 30 as severe bleeders. The phenotypic features of homozygotesg rouped for identical FVII genem utations that were present in at least2patients are providedinT able 4. Frequent mutations (Ala294Val, Ala294Val;11125delC, Cys310Phe) were associated with allclinical classesofseverity and neitherFVIIc levels (Table 4 ) nor genderorage provided an explanation for this heterogeneity.S ome heterogeneity in clotting activity is explained by the use of different thromboplastins, for instancei nArg304Gln homozygotes (Table 4) , tested with human and/or rabbit thromboplastins.However, plasma from patients homozygous for the Ala294Val;11125delC, Ala294Val and Cys310Phe mutations,the most frequent changes (Table 4) , were all testedwith human(placenta)orrecombinantthromboplastins.
Whena ne xtrinsic FXa generation assayw as performed using plasma samplesdrawn from 4patients carrying the same Ala294Va l;11125delCm utation and belonging to different severity classes(Table5), no differences were found.The very low butdetectable levelofFXa generation observedinplasma was confirmed by the expression of recombinant Ala294Val; 11125delC-FVII,o btained through mutagenesis: this recombinant mutant showedav eryr educed residuala ctivity level (0.3% of Wt-FVII).
Discussion
While several case series of severe FVII deficiencyh aveb een previously reported,this paperisthe first to analyze avirtually completeclinical spectrumofthis polymorphic disease.
We have also characterized the underlying FVII genelesions in al arge numbero fc ases and foundar emarkable number of previously unreported mutations.Throughout our analysis, genotype and zygosity information have beenu seda saw orking tool to extract distinct clinical phenotype information.
Multivariate analysis indicates thatclotting and clinical phenotypesofdouble heterozygotes and homozygotes arevirtually indistinguishablea nd that the vast majority of them( 85%) are symptomatic.
Our analysis revealed thatthe most common bleeding symptoms in FVII deficient patients are mild (i.e. hemorrhages of the mucous membranes and skin) ( Table 1) and thatepistaxis is by fart he most frequent presenting symptom. Life-threatening bleeds (CNS or GI, 20%ofpatients) are distinguishedfrom the otherbleeds by their earlypresentation (Fig. 1) and are associated with lowerFVIIc levels; in detail, theyoccur most frequently (65%and 70% of the cases) during the first 6months of life. In newbornpatients (< 1month), symptoms, ranked for frequency, were CNS, GI, cephal-hematomaand umbilicalbleeding.
HemarthrosisinFVII-deficient patients is clinicallyindistinguishable from that occurring in classical hemophilia, although much rarerand not gender-related. We found hemarthrosis to be most prevalent when children started to crawl or walk: 70% of FVII-deficient patients presenting with joint bleeds were less than5years of age. Theverylow FVIIc levels (median 1%, range 0.9-3%) found in patients with recurrent joint bleeds further supportthe importanceofthis symptom as amarker of severity.
Autosomallyinherited diseases offerthe opportunitytostudy the effect of gender on the clinical phenotype.Wefound ahigher prevalenceo ff emales amongs ymptomatic subjects ( Table 1 , Fig. 1 ) and in particular among moderate bleeders( Table3 ): mucho ft he excesso fb leeding tendencyc an be attributedt o menorrhagia,t he most frequent symptom in this gendera nd, though to al essere xtent, to gum bleeding and easyb ruising (Table 1) .InFVII deficient females withboth genesaffected,the prevalenceofmenorrhagia was60%, avalue similar to thatreported forfemalepatients with vonWillebrand Diseasetype III (69%, [21] ; 65%, [22] ) or factor XI deficiency(67%, [22] ). This suggests that FVII deficiencys hould be considereda sad eterminant of menorrhagia,e specially in the context of an egative pelvic examination finding. Therefore, when invasive procedures are planned in womenwith excessive genital blood losses, a hemostatic screening should be carriedo ut (ani solated prothrombin time is likelytodetect the deficiency).
Classification of patients according to clinical severity would allowfor grouping of patients with similar bleeding risk so thatt herapeutic strategies canb ea ssesseda nd improved. While in hemophilia classification of severity can be reliablydeterminedbyFVIII or FIXlevels, our analysis indicates thatFVII levels are significant determinants of the degree of severity but cannot be used to createu sefulc ut-offv alues forc linical purposes. Indeed,acut-offv alue (FVIIc 7.44%) wasrecently (23) proposed, basedon11severe patients. Theuse of this cut-off in our sample sizewould be poorlyinformative.
Becauseo ft his, we have setu pa ne mpiric classification basedonthe earlypresentation of the life-threatening and crippling symptoms (Table 2 ).This approachprovides aqualitative distinction between'severe' patients and the otherpatients, who were furtherclassifiedbythe number of "less severe" symptoms. MedianFVIIc values, significantly different betweenmild and moderate bleeders(Table3), and patient'szygosityfurther supportour classification. The earliness of presentation in severely affected patients providesanimportant argument in favour of an earlymanagement of the disease, prophylaxis included.
We found thatF VII gene polymorphisms, known to lower FVII levels in normals (14) , contribute significantly to the levels in the asymptomatic subjectsbut not in the symptomatic ones. Although these polymorphismscould contribute to clinicalheterogeneity,w ew ere unable to detect their influencei nc linical phenotypes, whichsuggests amajor clinical impact be played by the severe genelesions and environmental factors.
The variability in bleeding phenotypesamong homozygotes foridenticalmutations emphasizesthe clinicalheterogeneity of this disorder.Tobetterunderstand the genotype/phenotype relationship we performed amore careful evaluation of the clotting activity throughaFXa generation assayusing afluorogenicsubstrate;this sensitive method providedevidencefor asubstantial degree of functionalh omogeneity among the Ala294Val; 11125delC homozygotes, despite their differencesi nc linical phenotypes. Neitherplasma assays nor age and gender were able to explain clinicaldifferences in subjectsselected forthe presenceofidentical, homozygous mutations in FVII gene (Tabs 3 and 4).The arrayofphenotypesinpatients homozygousfor the same mutation and even forFVII haplotypes (FHand FB,unpublished results), still remains unexplained. These observations pointt oward the existenceo fe nvironmentalf actorsa nd/or of extra-genic( non-FVII gene)c omponents with the capacity of modifying the function of the clotting process and the expressivity of FVIIdeficiency.
